Home / World Marketplace / Archive by category Global Health & Biotech (Page 48)

Archive by category Global Health & Biotech

Bright Peak Therapeutics Presents New Data at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

– BPT958, a bifunctional PD-1 immunoconjugate with a masked IL-2 payload designed to be processed specifically in the tumor microenvironment - –In preclinical models, BPT958 induces potent antitumor activity with minimal systemic activation - BASEL, Switzerland and SAN DIEGO, Nov. 08, 2024 (Korea Bizwire) – Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering [...]

AskBio Receives FDA Rare Pediatric Disease and Orphan-Drug Designations for AB-1003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2I/R9

First patient dosed in Phase 1/Phase 2 LION-CS101 trial of AB-1003 in August 2023, with enrollment continuing Research Triangle Park, N.C., Nov. 07, 2024 (Korea Bizwire) – Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that AB-1003 (also known as LION-101) has received [...]

MedSource Labs Announces Groundbreaking Digital Training Assets for IV Catheters

MedSource Labs Unveils the most intensive remote training tools available to medical professionals, distributors and students. [Minneapolis, Minnesota, Chanhassen], Nov. 07, 2024 (Korea Bizwire) – MedSource Labs and its production partner, Ghost Medical, proudly announce the first training modules designed to improve patient care, comfort and clinician accuracy in peripheral IV Catheters. Through first-of-its-kind digital [...]

Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences

WALTHAM, Mass, Nov. 07, 2024 (Korea Bizwire) – Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced the Company’s participation at the following healthcare investor conferences: Guggenheim’s Inaugural Healthcare Innovation Conference on November 12, [...]

Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS

For an accessible version of this Press Release, please visit www.tevapharm.com Q3 2024 revenues of $4.3 billion reflect an increase of 13% in U.S. dollars, or 15% in local currency terms, compared to Q3 2023. AUSTEDO® – shows continued growth, U.S. revenues of $435 million in Q3 2024, an increase of 28% compared to Q3 2023; reaffirming [...]

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors

Global Phase 1 clinical trial will evaluate the safety and tolerability of ZW191 in treatment of advanced cancers including ovarian, endometrial, and non-small cell lung cancers VANCOUVER, British Columbia, Nov. 05, 2024 (Korea Bizwire) – Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard [...]

Philips enrolls first patient in U.S. clinical trial for innovative integrated single-device to treat peripheral artery disease

With a unique world-first ability to perform laser atherectomy and laser-based intravascular lithotripsy using a single device, Philips takes a major step forward in the treatment of peripheral artery disease (PAD) Cardiovascular Institute of the South successfully treats first patient in the U.S. using Philips’ innovative laser system, marking a milestone in advancing personalized care [...]

Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition

IMPACT-TD Registry, the largest study evaluating holistic effects of tardive dyskinesia (TD), highlights that there is a high burden of TD on quality of life regardless of a person’s underlying mental health condition Registry revealed fewer patients with psychotic disorders (36%) received TD diagnoses compared to those with mood disorders (50%) Teva continues to further [...]

Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-’749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as Results of Real-World Analyses of UZEDY® (risperidone)

Teva’s presentation of findings from six schizophrenia studies at Psych Congress 2024 highlights its commitment to finding new innovations in neuroscience Data show TEV-’749 drug delivery technology resulted in no occurrence of Post-Injection Delirium/Sedation Syndrome (PDSS) events to date Real-world analyses of UZEDY (risperidone) subcutaneous long-acting injectable reveal high adherence rates and utilization in adults [...]

Sabin Sends More Marburg Vaccines for Rwanda’s Outbreak

WASHINGTON, Oct. 31 (Korea Bizwire) — In continued collaboration with Rwanda to address the Marburg virus outbreak, the Sabin Vaccine Institute has dispatched approximately 1,000 additional investigational vaccine doses for a randomized clinical trial arm within the ongoing open-label study. More than 1,500 frontline workers have already been vaccinated in Rwanda with the Sabin vaccine. [...]